Bavarian Nordic (BAVA) Aperçu de l'action
Bavarian Nordic A/S développe, fabrique et fournit des vaccins vitaux. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 6/6 |
| Croissance future | 1/6 |
| Performances passées | 1/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
BAVA Community Fair Values
Create NarrativeSee what 43 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bavarian Nordic A/S Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | DKK 185.00 |
| Plus haut sur 52 semaines | DKK 244.80 |
| Plus bas sur 52 semaines | DKK 166.70 |
| Bêta | 0.96 |
| Variation sur 1 mois | 0.43% |
| Variation sur 3 mois | -5.47% |
| Variation sur 1 an | 9.37% |
| Variation sur 3 ans | 0.79% |
| Variation sur 5 ans | -28.57% |
| Évolution depuis l'introduction en bourse | -27.45% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 15
BAVA: Public Preparedness Contracts Will Support 2026 Earnings Upside
Analysts have kept their DKK 273.33 price target for Bavarian Nordic broadly unchanged, citing only minor adjustments to the discount rate, revenue growth assumptions and future P/E estimates in their valuation work. What's in the News Bavarian Nordic secured a government contract valued at over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine in 2026 and 2027, bringing Public Preparedness business contracts for 2026 to about DKK 2,200 million (Source: company announcement, recent news reports).Mise à jour du récit • Jun 01
BAVA: Public Preparedness Contracts And Vaccine Manufacturing Expansion Will Support 2026 Upside
Analysts have nudged their fair value estimate for Bavarian Nordic higher from DKK 268.33 to DKK 273.33. They point to adjusted assumptions around revenue growth, profit margins and future P/E as the main drivers of the updated price target.Recent updates
Mise à jour du récit • Jun 15
BAVA: Public Preparedness Contracts Will Support 2026 Earnings Upside
Analysts have kept their DKK 273.33 price target for Bavarian Nordic broadly unchanged, citing only minor adjustments to the discount rate, revenue growth assumptions and future P/E estimates in their valuation work. What's in the News Bavarian Nordic secured a government contract valued at over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine in 2026 and 2027, bringing Public Preparedness business contracts for 2026 to about DKK 2,200 million (Source: company announcement, recent news reports).Mise à jour du récit • Jun 01
BAVA: Public Preparedness Contracts And Vaccine Manufacturing Expansion Will Support 2026 Upside
Analysts have nudged their fair value estimate for Bavarian Nordic higher from DKK 268.33 to DKK 273.33. They point to adjusted assumptions around revenue growth, profit margins and future P/E as the main drivers of the updated price target.
Mise à jour du récit • May 16
BAVA: Public Preparedness Contracts And Vaccine Approvals Will Support Higher Future Returns
Analysts have kept their DKK 280 price target for Bavarian Nordic unchanged, pointing to slightly higher assumed revenue growth and profit margins, along with a modestly higher discount rate and a lower future P/E expectation as key inputs behind the refreshed valuation work. What's in the News Bavarian Nordic raised its earnings guidance for 2026, now expecting revenue of DKK 5,500 million to DKK 5,700 million, compared with the earlier range of DKK 5,000 million to DKK 5,200 million.
Mise à jour du récit • Apr 30
BAVA: Vaccine Approvals And Capacity Expansion Will Drive Future Upside
Analysts have kept their DKK 250.00 price target for Bavarian Nordic unchanged. They point to only small tweaks to assumptions on discount rate, revenue contraction, profit margin and future P/E, which they view as largely offsetting each other.Mise à jour du récit • Apr 16
BAVA: Expanded Vaccine Manufacturing Partnership Will Support 2026 Upside
Analysts have kept their DKK price target for Bavarian Nordic effectively unchanged, with a DKK 0.00 net move. Small tweaks to the discount rate and future P/E assumptions offset each other in their updated valuation work.Mise à jour du récit • Apr 01
BAVA: Expanded Vaccine Pipeline And New Contracts Will Support Higher Future Returns
Analysts have raised their price target on Bavarian Nordic from DKK 244.00 to DKK 280.00. They cite updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that they view as better reflecting the company’s current outlook.Mise à jour du récit • Mar 18
BAVA: Expanded Vaccine Partnerships And 2026 Orders Will Support Upside
Analysts have raised their price target on Bavarian Nordic from DKK 265 to about DKK 268, reflecting adjustments to their valuation inputs, including a slightly higher discount rate, a modest change to revenue growth expectations and a marginally different assumed future P/E and profit margin profile. What's in the News Bavarian Nordic expanded its partnership with Serum Institute of India to include full tech transfer and contract manufacturing for the chikungunya vaccine CHIKV VLP, aiming to scale capacity for future supply to endemic low and middle income countries.Mise à jour du récit • Mar 04
BAVA: Buybacks And Latin America Vaccine Deal Will Drive Future Upside
Analysts have maintained their DKK 250 price target on Bavarian Nordic, citing only minor adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E as the reasons for this stable assessment. What's in the News CEO Paul Chaplin plans to step down for personal reasons, and the Board has agreed that he will stay in the role through the end of 2026 or until a successor is appointed.Mise à jour du récit • Feb 18
BAVA: Share Buybacks And Latin America Vaccine Deal Will Support Upside
Analysts now keep their DKK 250 price target for Bavarian Nordic intact, as slightly higher discount and future P/E assumptions together with a modestly stronger profit margin view offset softer revenue growth expectations. What's in the News Bavarian Nordic issued earnings guidance for fiscal 2026, indicating expected revenue in the range of DKK 5,000 million to DKK 5,200 million (Corporate guidance).Mise à jour du récit • Feb 03
BAVA: Latin America Vaccine Deal Will Support Future Earnings Upside
Analysts have nudged their price target on Bavarian Nordic higher to €265, up from €260, citing updated assumptions on discount rates, revenue expectations, profit margins and forward P/E multiples. What's in the News Bavarian Nordic signed an agreement with Eurofarma, giving Eurofarma exclusive rights to sell and distribute the chikungunya vaccine CHIKV VLP, marketed as VIMKUNYA, in Brazil, along with a right of first refusal for future Latin American opportunities, on a transfer price and royalty basis with no upfront or milestone payments (Key Developments).Mise à jour du récit • Jan 20
BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings
Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.Mise à jour du récit • Jan 06
BAVA: HERA Procurement Contract And Mpox Demand Are Expected To Drive Upside
Analysts have kept their price target for Bavarian Nordic unchanged at €260. This reflects only small tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions rather than a shift in their overall view.Mise à jour du récit • Dec 16
BAVA: Mpox Preparedness Contracts Will Underpin Stronger Long Term Earnings Power
Analysts have raised their price target on Bavarian Nordic from approximately $225 to about $250. This reflects a higher justified valuation multiple despite expectations for softer revenue growth and margins.Mise à jour du récit • Dec 02
BAVA: Procurement Agreement And Margin Outlook Signal Upside For Shares
Analysts have raised their price target for Bavarian Nordic from €250 to €260. They cite improvements in projected profit margins and lower expected future price-to-earnings ratios, even though there is a modest increase in the discount rate and a slightly weaker revenue growth outlook.Mise à jour du récit • Oct 24
Local Spread Of New Mpox Strain Will Challenge Future Vaccine Margins
Narrative Update on Bavarian Nordic Analysts have raised their fair value price target for Bavarian Nordic from €244 to €250, citing modest improvements in valuation assumptions and financial projections. What's in the News Officials in California have confirmed community spread of the new clade 1 Mpox strain among residents with no recent international travel.Mise à jour du récit • Aug 27
VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues
Despite a deterioration in consensus revenue growth forecasts, a modest improvement in net profit margin has supported a slight increase in Bavarian Nordic's fair value, with the target price rising from DKK234.50 to DKK244.00. What's in the News Nordic Capital and Permira have proposed to acquire Bavarian Nordic for DKK 18.1 billion (DKK 233 per share), a 21% premium to the prior closing price; board and management have agreed to tender their shares, and a delisting is planned upon completion, subject to customary conditions.Article d’analyse • Jul 28
Bavarian Nordic A/S (CPH:BAVA) Held Back By Insufficient Growth Even After Shares Climb 38%
Despite an already strong run, Bavarian Nordic A/S ( CPH:BAVA ) shares have been powering on, with a gain of 38% in the...Article d’analyse • Jun 13
Earnings Working Against Bavarian Nordic A/S' (CPH:BAVA) Share Price
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...Article d’analyse • Apr 03
Here's Why Shareholders May Want To Be Cautious With Increasing Bavarian Nordic A/S' (CPH:BAVA) CEO Pay Packet
Key Insights Bavarian Nordic's Annual General Meeting to take place on 9th of April Total pay for CEO Paul Chaplin...Article d’analyse • Mar 13
Bavarian Nordic's (CPH:BAVA) Soft Earnings Are Actually Better Than They Appear
The market for Bavarian Nordic A/S' ( CPH:BAVA ) shares didn't move much after it posted weak earnings recently. We...Article d’analyse • Mar 08
Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Bavarian Nordic A/S ( CPH:BAVA ) came out with its yearly results last week, and we wanted to see how the business is...
Nouveau récit • Feb 10
Chikungunya Vaccine Launch And Market Expansion Will Open Opportunities But Mpox Demand Uncertainties Could Pose Risks
The chikungunya vaccine launch and expansion into new markets could significantly drive revenue and broaden customer base.Article d’analyse • Dec 14
Getting In Cheap On Bavarian Nordic A/S (CPH:BAVA) Is Unlikely
With a median price-to-earnings (or "P/E") ratio of close to 14x in Denmark, you could be forgiven for feeling...Article d’analyse • Nov 16
Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Aug 26
Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher
Bavarian Nordic A/S ( CPH:BAVA ) shareholders have had their patience rewarded with a 53% share price jump in the last...Article d’analyse • Aug 25
Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Bavarian Nordic A/S ( CPH:BAVA ) released its quarterly result to the market. The...Rendement pour les actionnaires
| BAVA | DK Biotechs | DK Marché | |
|---|---|---|---|
| 7D | 3.9% | 5.4% | 2.5% |
| 1Y | 9.4% | 23.0% | -10.5% |
Rendement vs Industrie: BAVA a sous-performé le secteur Danish Biotechs qui a rapporté 23 % au cours de l'année écoulée.
Rendement vs marché: BAVA a dépassé le marché Danish qui a rapporté -10.5 % au cours de l'année écoulée.
Volatilité des prix
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 8.0% |
| 10% least volatile stocks in DK Market | 2.5% |
Cours de l'action stable: BAVA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Danish.
Volatilité au fil du temps: La volatilité hebdomadaire de BAVA ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1992 | 1,861 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S développe, fabrique et fournit des vaccins vitaux. L'entreprise propose des vaccins antivarioliques et antivarioliques non réplicatifs sous les noms IMVAMUNE, IMVANEX et JYNNEOS ; un vaccin antirabique à usage humain sous le nom Rabipur/RabAvert ; un vaccin contre l'encéphalite à tiques sous le nom Encepur ; Vaxchora, un vaccin oral pour l'immunisation contre le choléra ; et Vivotif/Typhoral, un vaccin oral pour l'immunisation contre la fièvre typhoïde. Elle développe également MVA-BN WEV pour le traitement des virus de l'encéphalite.
Bavarian Nordic A/S Résumé des fondamentaux
| BAVA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | DKK 14.15b |
| Bénéfices(TTM) | DKK 1.17b |
| Recettes(TTM) | DKK 5.96b |
12.1x
Ratio P/E2.4x
Ratio P/SLe site BAVA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| BAVA compte de résultat (TTM) | |
|---|---|
| Recettes | DKK 5.96b |
| Coût des recettes | DKK 3.09b |
| Marge brute | DKK 2.87b |
| Autres dépenses | DKK 1.69b |
| Les revenus | DKK 1.17b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Aug 21, 2026
| Résultat par action (EPS) | 15.34 |
| Marge brute | 48.11% |
| Marge bénéficiaire nette | 19.71% |
| Ratio dettes/capitaux propres | 0.1% |
Quelles ont été les performances à long terme de BAVA?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/01 06:53 |
| Cours de l'action en fin de journée | 2026/07/01 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bavarian Nordic A/S est couverte par 13 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jacob Lademann | Carnegie Investment Bank AB |
| Peter Verdult | Citigroup Inc |
| Hakon Hemme Jørgensen | Danske Bank |